Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT05876585

Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

A Randomized, Double-Blinded, Placebo-Controlled, Phase III Clinical Trial to Investigate the Efficacy and Safety of Ondansetron (Danset - Adwia) Versus Placebo Plus the Standard of Care in the Treatment of Nausea and Vomiting in Adult Patients With Acute Gastroenteritis

Status
Not Yet Recruiting
Phase
Phase 3
Study type
Interventional
Enrollment
126 (estimated)
Sponsor
Genuine Research Center, Egypt · Industry
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Not accepted

Summary

A Randomized, Open-label, Active-Controlled Clinical Trial to Investigate the Efficacy and Safety of Ondansetron compared to Metoclopramide in the management of Nausea and Vomiting in Adult Patients with Acute Gastroenteritis.

Detailed description

This is a phase III, randomized, open-label, active-controlled, two-arm, parallel-design, interventional clinical trial evaluating the efficacy and safety of ondansetron 8 mg IV/ IM injection compared to metoclopramide 10 mg in the management of nausea and vomiting in adult patients with acute gastroenteritis. Study duration: 1 year for patients' enrollment and follow-up. Sample Size: 63 subjects per arm, 126 in total. Participants in the trial will be male and female patients aged between 18 and 65 years visiting the emergency room due to acute gastroenteritis. Patients will be screened for eligibility and eligible patients will be randomized in a 1:1 allocation ratio to receive a single dose of ondansetron 8 mg injection (arm 1) or a single dose of metoclopramide 10 mg injection (arm 2). Randomization will be done using interactive web response technology. After drug administration, the patients will be followed up for 24 hours, including at least 3 hours in the emergency room immediately after drug administration.

Conditions

Interventions

TypeNameDescription
DRUGOndansetron 8 mg ampouleStudy drug
DRUGMetoclopramide 10 mg ampouleComparator drug

Timeline

Start date
2025-06-01
Primary completion
2025-06-01
Completion
2025-06-01
First posted
2023-05-25
Last updated
2024-09-26

Source: ClinicalTrials.gov record NCT05876585. Inclusion in this directory is not an endorsement.